Is VTRS or LEGN more profitable?

Viatris has a net margin of -2.04% compared to Legend Biotech's net margin of -21.98%. Viatris' return on equity of 19.04% beat Legend Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% Legend Biotech -21.98% -24.92% -14.87%

Does the media favor VTRS or LEGN?

In the previous week, Legend Biotech had 4 more articles in the media than Viatris. MarketBeat recorded 7 mentions for Legend Biotech and 3 mentions for Viatris. Viatris' average media sentiment score of 1.10 beat Legend Biotech's score of 1.04 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, LEGN or GMAB?

Genmab A/S has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Legend Biotech $1.03B 4.65 -$296.80M -$0.68 N/A Genmab A/S $3.72B 4.83 $963M $1.32 21.82

Is LEGN or GMAB more profitable?

Genmab A/S has a net margin of 21.05% compared to Legend Biotech's net margin of -21.98%. Genmab A/S's return on equity of 15.34% beat Legend Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Legend Biotech -21.98% -24.92% -14.87% Genmab A/S 21.05% 15.34% 8.94%

Does the media prefer LEGN or GMAB?

In the previous week, Legend Biotech had 2 more articles in the media than Genmab A/S. MarketBeat recorded 7 mentions for Legend Biotech and 5 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.16 beat Legend Biotech's score of 1.04 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ASND or LEGN?

In the previous week, Ascendis Pharma A/S and Ascendis Pharma A/S both had 7 articles in the media. Legend Biotech's average media sentiment score of 1.04 beat Ascendis Pharma A/S's score of 1.01 indicating that Legend Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BBIO or LEGN?

In the previous week, BridgeBio Pharma had 11 more articles in the media than Legend Biotech. MarketBeat recorded 18 mentions for BridgeBio Pharma and 7 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 1.04 beat BridgeBio Pharma's score of 0.70 indicating that Legend Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LEGN or AXSM?

In the previous week, Axsome Therapeutics had 5 more articles in the media than Legend Biotech. MarketBeat recorded 12 mentions for Axsome Therapeutics and 7 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 1.04 beat Axsome Therapeutics' score of 0.75 indicating that Legend Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Legend Biotech (LEGN) Competitors

$25.75 -1.33 (-4.91%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$25.64 -0.11 (-0.43%)

As of 07/13/2026 07:55 PM Eastern

Compare

LEGN vs. VTRS, GMAB, ASND, BBIO, and AXSM

Should you buy Legend Biotech stock or one of its competitors? MarketBeat compares Legend Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Legend Biotech include Viatris (VTRS), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

How does Legend Biotech compare to Viatris?

Viatris (NASDAQ:VTRS) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Viatris presently has a consensus price target of $17.50, indicating a potential upside of 6.77%. Legend Biotech has a consensus price target of $57.00, indicating a potential upside of 121.36%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Legend Biotech is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Legend Biotech	1 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.60

Legend Biotech has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.33	-$3.51B	-$0.26	N/A
Legend Biotech	$1.03B	4.65	-$296.80M	-$0.68	N/A

Viatris has a net margin of -2.04% compared to Legend Biotech's net margin of -21.98%. Viatris' return on equity of 19.04% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Legend Biotech	-21.98%	-24.92%	-14.87%

79.9% of Viatris shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Viatris has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

In the previous week, Legend Biotech had 4 more articles in the media than Viatris. MarketBeat recorded 7 mentions for Legend Biotech and 3 mentions for Viatris. Viatris' average media sentiment score of 1.10 beat Legend Biotech's score of 1.04 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Viatris beats Legend Biotech on 9 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to Genmab A/S?

Legend Biotech (NASDAQ:LEGN) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

Genmab A/S has a net margin of 21.05% compared to Legend Biotech's net margin of -21.98%. Genmab A/S's return on equity of 15.34% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Genmab A/S	21.05%	15.34%	8.94%

Genmab A/S has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	4.65	-$296.80M	-$0.68	N/A
Genmab A/S	$3.72B	4.83	$963M	$1.32	21.82

Legend Biotech currently has a consensus target price of $57.00, indicating a potential upside of 121.36%. Genmab A/S has a consensus target price of $38.21, indicating a potential upside of 32.69%. Given Legend Biotech's higher probable upside, analysts plainly believe Legend Biotech is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.60
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Legend Biotech had 2 more articles in the media than Genmab A/S. MarketBeat recorded 7 mentions for Legend Biotech and 5 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.16 beat Legend Biotech's score of 1.04 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Legend Biotech has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Genmab A/S beats Legend Biotech on 13 of the 17 factors compared between the two stocks.

How does Legend Biotech compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Ascendis Pharma A/S has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	20.31	-$258M	$8.67	30.59
Legend Biotech	$1.03B	4.65	-$296.80M	-$0.68	N/A

Ascendis Pharma A/S has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

Ascendis Pharma A/S currently has a consensus target price of $295.67, suggesting a potential upside of 11.48%. Legend Biotech has a consensus target price of $57.00, suggesting a potential upside of 121.36%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Legend Biotech	1 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.60

Ascendis Pharma A/S has a net margin of 57.87% compared to Legend Biotech's net margin of -21.98%. Ascendis Pharma A/S's return on equity of 0.00% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Legend Biotech	-21.98%	-24.92%	-14.87%

In the previous week, Ascendis Pharma A/S and Ascendis Pharma A/S both had 7 articles in the media. Legend Biotech's average media sentiment score of 1.04 beat Ascendis Pharma A/S's score of 1.01 indicating that Legend Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.9% of Legend Biotech shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Ascendis Pharma A/S beats Legend Biotech on 12 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

BridgeBio Pharma has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

BridgeBio Pharma presently has a consensus price target of $94.63, suggesting a potential upside of 13.90%. Legend Biotech has a consensus price target of $57.00, suggesting a potential upside of 121.36%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Legend Biotech	1 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.60

Legend Biotech has higher revenue and earnings than BridgeBio Pharma. Legend Biotech is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	32.41	-$724.93M	-$3.74	N/A
Legend Biotech	$1.03B	4.65	-$296.80M	-$0.68	N/A

Legend Biotech has a net margin of -21.98% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Legend Biotech	-21.98%	-24.92%	-14.87%

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BridgeBio Pharma had 11 more articles in the media than Legend Biotech. MarketBeat recorded 18 mentions for BridgeBio Pharma and 7 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 1.04 beat BridgeBio Pharma's score of 0.70 indicating that Legend Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BridgeBio Pharma beats Legend Biotech on 9 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to Axsome Therapeutics?

Legend Biotech (NASDAQ:LEGN) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, Axsome Therapeutics had 5 more articles in the media than Legend Biotech. MarketBeat recorded 12 mentions for Axsome Therapeutics and 7 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 1.04 beat Axsome Therapeutics' score of 0.75 indicating that Legend Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Legend Biotech has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

Legend Biotech has a net margin of -21.98% compared to Axsome Therapeutics' net margin of -26.59%. Legend Biotech's return on equity of -24.92% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Axsome Therapeutics has lower revenue, but higher earnings than Legend Biotech. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	4.65	-$296.80M	-$0.68	N/A
Axsome Therapeutics	$638.50M	18.40	-$183.17M	-$3.73	N/A

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Legend Biotech currently has a consensus target price of $57.00, indicating a potential upside of 121.36%. Axsome Therapeutics has a consensus target price of $259.05, indicating a potential upside of 13.48%. Given Legend Biotech's higher possible upside, equities research analysts clearly believe Legend Biotech is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.60
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

Summary

Axsome Therapeutics beats Legend Biotech on 9 of the 17 factors compared between the two stocks.

Get Legend Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LEGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LEGN vs. The Competition

Export

Metric	Legend Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.03B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-37.87	20.85	27.11	24.26
Price / Sales	4.65	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	4.74	8.49	10.75	6.29
Net Income	-$296.80M	$23.83M	$3.58B	$330.66M
7 Day Performance	-6.97%	-3.56%	-2.06%	-1.32%
1 Month Performance	-28.21%	6.31%	3.32%	-0.64%
1 Year Performance	-34.71%	48.30%	26.35%	19.08%

Legend Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LEGN Legend Biotech	3.5135 of 5 stars	$25.75 -4.9%	$57.00 +121.4%	-33.9%	$5.03B	$1.03B	N/A	2,965	News Coverage Positive News Analyst Forecast
VTRS Viatris	2.7092 of 5 stars	$16.80 +0.6%	$17.50 +4.2%	+79.7%	$19.45B	$14.30B	N/A	30,000	Positive News
GMAB Genmab A/S	4.585 of 5 stars	$28.01 -1.8%	$38.21 +36.4%	+34.6%	$17.78B	$3.72B	20.51	3,029	Positive News
ASND Ascendis Pharma A/S	4.3684 of 5 stars	$267.92 -2.4%	$295.39 +10.3%	+51.6%	$17.12B	$814.57M	30.90	1,189
BBIO BridgeBio Pharma	3.1076 of 5 stars	$77.75 +0.7%	$92.90 +19.5%	+78.8%	$15.12B	$502.08M	N/A	400	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LEGN) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Legend Biotech (LEGN) Competitors

LEGN vs. VTRS, GMAB, ASND, BBIO, and AXSM

How does Legend Biotech compare to Viatris?

Summary

How does Legend Biotech compare to Genmab A/S?

Summary

How does Legend Biotech compare to Ascendis Pharma A/S?

Summary

How does Legend Biotech compare to BridgeBio Pharma?

Summary

How does Legend Biotech compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN vs. The Competition

Legend Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Legend Biotech (LEGN) Competitors

LEGN vs. VTRS, GMAB, ASND, BBIO, and AXSM

How does Legend Biotech compare to Viatris?

Do analysts rate VTRS or LEGN?

Which has stronger valuation & earnings, VTRS or LEGN?

Is VTRS or LEGN more profitable?

Do institutionals & insiders believe in VTRS or LEGN?

Which has more risk and volatility, VTRS or LEGN?

Does the media favor VTRS or LEGN?

Summary

How does Legend Biotech compare to Genmab A/S?

Is LEGN or GMAB more profitable?

Which has stronger earnings & valuation, LEGN or GMAB?

Do analysts prefer LEGN or GMAB?

Does the media prefer LEGN or GMAB?

Which has more volatility & risk, LEGN or GMAB?

Do institutionals and insiders believe in LEGN or GMAB?

Summary

How does Legend Biotech compare to Ascendis Pharma A/S?

Which has stronger earnings & valuation, ASND or LEGN?

Which has more volatility and risk, ASND or LEGN?

Do analysts prefer ASND or LEGN?

Is ASND or LEGN more profitable?

Does the media refer more to ASND or LEGN?

Do institutionals & insiders hold more shares of ASND or LEGN?

Summary

How does Legend Biotech compare to BridgeBio Pharma?

Which has more volatility & risk, BBIO or LEGN?

Do analysts prefer BBIO or LEGN?

Which has preferable valuation & earnings, BBIO or LEGN?

Is BBIO or LEGN more profitable?

Do institutionals and insiders hold more shares of BBIO or LEGN?

Does the media favor BBIO or LEGN?

Summary

How does Legend Biotech compare to Axsome Therapeutics?

Does the media prefer LEGN or AXSM?

Which has more risk & volatility, LEGN or AXSM?

Is LEGN or AXSM more profitable?

Which has preferable earnings & valuation, LEGN or AXSM?

Do institutionals & insiders have more ownership in LEGN or AXSM?

Do analysts recommend LEGN or AXSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN vs. The Competition

Legend Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools